ATF3 and cancer: These results were validated in vivo using a model of subcutaneously implanted gastric (TMK-1), or pancreatic (L3.6pl) cancer cells where Hsp90 inhibitor treatment markedly induced ATF3 expression in respective tumors (Figure 1B).